Why it matters: The move threatens telehealth companies compounded GLP-1 weight loss drug sales and benefits brand drugmakers that have pushed against those sales
Pursuant to the terms of an annual evergreen provision in the 2014 Plan, the number of shares of common stock available for issuance under the 2014 Plan shall automatically increase on January 1 of each year by at least seven percent ( On January 1, 2023, pursuant to an annual evergreen provision contained in the 2014 Plan, the number of shares reserved for future grants was increased by In accordance with the terms of the 2014 Plan, effective as of January 1, 2024, the number of shares of common stock available for issuance under the 2014 Plan increased by F-23 Stock-based Compensation In connection with all stock-based compensation awards, total non-cash, stock-based compensation expense, net of estimated forfeitures, recognized in the consolidated statements of operations and comprehensive loss for the years ended December 31, 2023 and 2022 was as follows: The total stock-based compensation expense recognized by award type was as follows: Stock Options The fair value of each option award is estimated on the date of grant using the Black-Scholes option pricing model that uses the assumptions noted in the following table, except for the expected term for non-employees as noted in the following paragraph
PMID: 37269385
For patients with existing risk factors, these shifts may also trigger gallbladder inflammation
Many skincare products now incorporate peptides for their anti-aging benefits
Workspan Daily article Strategies to Deliver Diabetes Support and Solutions for Employees, Workspan Daily article Fifty-one percent of employers in a recent benefits study cited glucagon-like peptide-1 (GLP-1) diabetes and weight-loss medications as the top driver of prescription drug spend, surpassing even cancer and autoimmune treatments
